65,437 trials
Pain, Postoperative
Primary: Wake Time After Sleep Onset (WASO) Measured by Actigraphy — 155.25; 180.08; 364.83 Minutes — p=0.3047
Pulmonary Disease, Chronic Obstructive
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 85 (12 Weeks) — 0.008; 0.159; 0.152 Liter — p=<0.0001
Type 2 Diabetes
Primary: Total Norm AUC Average by Group (Normalized) — 150.8; 175.9; 149.9; 175.1 mg/(dL/hr) normalized
Breast Cancer
Primary: Progression-Free Survival (PFS) — 9.5; 8.2 months — p=0.077
Gout
Primary: Safety of Allopurinol — 55.1 percentage of subjects
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) on Norethisterone of NPC-01 — 69.183 ng･hr/mL
Colorectal Carcinoma
Primary: Progression-Free Survival (PFS) — 11.5 months
Diabetes Mellitus, Type 2
Primary: Number of Patients With Drug Related Adverse Events — 19; 25; 13; 13 participants
Elevated Cardiac Risk · Coronary Arteries Disease Risk
Primary: Number of Participants With Myocardial Necrosis (MN) — 57; 54 participants — p=0.0052
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12 — 21.2; 33.0 percentage of participants — p=0.055
Dysmenorrhea
Primary: Patient Response to Treatment for Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment) — 4.1; 4.2; 1.8; 2.9…
Cigarette Smoking
Primary: Continuous Rate of Smoking Cessation by Self-report and Confirmed by Expired Air Carbon Monoxide Less or Equal Than 8 Ppm — 5; 2 participants
Hypertension
Primary: Change in Oral Glucose Tolerance Test (OGTT) Area Under Curve (AUC) After Addition of Trandolapril to Hydrochlorothiazide (HCTZ) Compared With Change in OGTT AUC After…
Healthy
Primary: Digoxin: Area Under the Curve 0 to Infinity (AUC0-∞) — 37.8; 39.9 ng-h/mL
Pain, Postoperative
Primary: Wake Time After Sleep Onset (WASO) Measured by Actigraphy — 143.7; 230.9; 214.0; 431.4 Minutes — p=0.0002